TY - JOUR
T1 - Clinical pattern and treatment outcome of Cutaneous Leishmaniasis in two hospitals in Bahir Dar, Ethiopia (2017-2021)
AU - Tesfa, Debas
AU - Manaye, Nigus
AU - de Vries, Henry Jc
AU - van Griensven, Johan
AU - Enbiale, Wendemagegn
N1 - Funding Information: The program was funded by TDR, the Special Programme for Research and Training in Tropical Diseases and the Institute of Tropical Medicine Antwerp. Funding Information: This study was carried out as part of the Structured Operational Research and Training Initiative (SORT IT), a global collaboration led by TDR, the World Health Organization's Special Programme for Research and Training in Tropical Diseases. A collaborative implementation partnership between TDR the Institute of Tropical Medicine Antwerp, Belgium, the WHO country office in Ethiopia, and the International Union against Tuberculosis and Lung Disease, Paris, France, resulted in these publications. We would like to thank Dr. Yared Getachew, Dr. Wossen Ketema, Dr. Asressie Mamo, Dr. Mihreteab Beza, and other BDU Dermato-venereology residents, as well as other department members, for assisting with data collection and documentation. Publisher Copyright: Copyright © 2022 Tesfa et al.
PY - 2022/8/31
Y1 - 2022/8/31
N2 - Introduction: Cutaneous Leishmaniasis (CL) in Ethiopia is caused by a unique species, L. aethiopica. In Ethiopia, there are limited studies that provide detailed clinical descriptions of CL, treatment options, and treatment outcomes. Methodology: We conducted a descriptive study based on routinely collected data in medical files from two hospitals in Bahir Dar, Ethiopia, from 2017 to 2021. Three months following the end of therapy, we retrieved sociodemographic and clinical data, as well as data on the treatment outcome. Result: Between March 2017 and June 2021, 94 patients were diagnosed with CL at the two hospitals. Of those, 46 (48.9%) of individuals had localized CL, 36 (38.3%) mucocutaneous leishmaniasis (MCL), and 12 (12.8%) diffuse CL. Sixty-five (69.1%) of the participants were men. The most prevalent morphologic appearances were plaque (n = 42, 46.2%), nodule (n = 38, 41.8%), infiltrative (n = 34, 36.2%), crusted (n = 32, 34%), and ulcerated (n = 24, 25.5%). Scarred, volcanic, and patchy lesions were also documented. Systemic pentavalent antimonials were the most common treatment (n = 55, 58.5%), curing 21/38 (55%) of the patients. Pentavalent antimonials were also given intralesionally to seventeen patients (18.1%), with 15/16 (94%) of them being cured. Overall, 61% (40/66) of patients with documented treatment outcomes were cured. Conclusions: As CL in Ethiopia has a wide array of clinical presentations, clinicians should be suspicious of patients from endemic areas who present with dermatologic manifestations. Physicians can employ local treatment as a first line before resorting to systemic therapy.
AB - Introduction: Cutaneous Leishmaniasis (CL) in Ethiopia is caused by a unique species, L. aethiopica. In Ethiopia, there are limited studies that provide detailed clinical descriptions of CL, treatment options, and treatment outcomes. Methodology: We conducted a descriptive study based on routinely collected data in medical files from two hospitals in Bahir Dar, Ethiopia, from 2017 to 2021. Three months following the end of therapy, we retrieved sociodemographic and clinical data, as well as data on the treatment outcome. Result: Between March 2017 and June 2021, 94 patients were diagnosed with CL at the two hospitals. Of those, 46 (48.9%) of individuals had localized CL, 36 (38.3%) mucocutaneous leishmaniasis (MCL), and 12 (12.8%) diffuse CL. Sixty-five (69.1%) of the participants were men. The most prevalent morphologic appearances were plaque (n = 42, 46.2%), nodule (n = 38, 41.8%), infiltrative (n = 34, 36.2%), crusted (n = 32, 34%), and ulcerated (n = 24, 25.5%). Scarred, volcanic, and patchy lesions were also documented. Systemic pentavalent antimonials were the most common treatment (n = 55, 58.5%), curing 21/38 (55%) of the patients. Pentavalent antimonials were also given intralesionally to seventeen patients (18.1%), with 15/16 (94%) of them being cured. Overall, 61% (40/66) of patients with documented treatment outcomes were cured. Conclusions: As CL in Ethiopia has a wide array of clinical presentations, clinicians should be suspicious of patients from endemic areas who present with dermatologic manifestations. Physicians can employ local treatment as a first line before resorting to systemic therapy.
KW - Addis Alem Hospital
KW - DCL
KW - LCL
KW - MCL treatment
KW - SORT IT
KW - operational research
UR - http://www.scopus.com/inward/record.url?scp=85138657536&partnerID=8YFLogxK
U2 - https://doi.org/10.3855/jidc.15979
DO - https://doi.org/10.3855/jidc.15979
M3 - Article
C2 - 36156499
SN - 2036-6590
VL - 16
SP - 26S-34S
JO - Journal of infection in developing countries
JF - Journal of infection in developing countries
IS - 81
ER -